Tag Archives: Biomea Fusion

JPM 2026 Day 4: IVA, JNGHF, LXRX, BMEA, ESPR; FDA Delays CNPV Approvals

On the fourth and final day of JPM 2026, FENIX has provided coverage of presentations by Inventiva Pharma, Jiangsu Hengrui Pharmaceuticals, Lexicon Pharmaceuticals, Biomea Fusion, and Esperion. Separately, one CVRM-related news item has been observed: FDA has delayed CNPV approval of Tzield and orforglipron (view article). Below, FENIX provides highlights and insights from the JPM presentations as well as insight into the CNPV delays.

This content is for Read Less members only.
Register
Already a member? Log in here

Pfizer Faces Legal Setback in Metsera Battle, Set to Submit New Bid; MannKind and Biomea Q3 ‘25 Earnings

Three cardiometabolic-related news items have been observed: A Delaware court denied Pfizer’s request to temporarily block Novo’s amended bid for Metsera (press release); MannKind hosted its Q3 ‘25 earnings call (press release; slides); and Biomea Fusion released its Q3 ‘25 earnings report  (view press release).  Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Lilly Taps Shaq for OSA Awareness; Biomea Doses First Patient with Oral GLP-1RA; Fibronostics Acquisition for MASH Diagnostics 

Three cardiometabolic-related news items have been observed: Lilly launched a new OSA campaign with Shaquille O’Neal titled, “Don’t Sleep on OSA” (view press release); Biomea Fusion dosed the first patient in its Ph1 study of BMF-650 (QD oral GLP-1RA) in otherwise healthy overweight/obese patients (view press release); and Fibronostics completed the acquisition of Stone Clinical Laboratories for non-invasive diagnostic testing for MASH/MASLD (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Biomea Ph2 T2DM Results; AZ Ph3 Baxdrostat Data; Ionis 2025 Innovation Day; New Hanmi Ph2 Triple Agonist Study; MannKind Completes scPharmaceuticals Acquisition; Fractyl Health Preclinical Gene Therapy Data 

A series of cardiometabolic-related news items has been observed from Biomea Fusion, AstraZeneca, Ionis Pharmaceuticals, Hanmi Pharmaceuticals, Fractyl Health, and MannKind. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here

Dexcom Integrates AI Into Stelo; Biomea Topline Icovamenib T2DM Data

Two cardiometabolic-related news items have been observed: Dexcom announced it is integrating Generative AI (GenAI) into its Stelo CGM platform to analyze individual health data patterns (view press release); and Biomea Fusion announced positive topline results from the ongoing COVALENT-111 study in T2DM (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here